Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMetser, Ur-
dc.contributor.authorChua, Sue-
dc.contributor.authorHo, Bao-
dc.contributor.authorPunwani, Shonit-
dc.contributor.authorJohnston, Edward-
dc.contributor.authorPouliot, Frederic-
dc.contributor.authorTau, Noam-
dc.contributor.authorHawsawy, Asmaa-
dc.contributor.authorAnconina, Reut-
dc.contributor.authorBauman, Glenn-
dc.contributor.authorHicks, Rodney J-
dc.contributor.authorWeickhardt, Andrew J-
dc.contributor.authorDavis, Ian D-
dc.contributor.authorPond, Greg-
dc.contributor.authorScott, Andrew M-
dc.contributor.authorTunariu, Nina-
dc.contributor.authorSidhu, Harbir-
dc.contributor.authorEmmett, Louise-
dc.identifier.citationJournal of nuclear medicine : official publication, Society of Nuclear Medicine 2019; 60(9): 1253-1258-
dc.description.abstractOur purpose was to assess whether the addition of data from multiparametric pelvic MRI (mpMR) and whole-body MRI (wbMR) to the interpretation of 18F-fluoromethylcholine (18F-FCH) or 68Ga-HBED-CC PSMA-11 (68Ga-PSMA) PET/CT (=PET) improves the detection of local tumor recurrence or of nodal and distant metastases in patients after radical prostatectomy with biochemical failure. Methods: The current analysis was performed as part of a prospective, multicenter trial on 18F-FCH or 68Ga-PSMA PET, mpMR, and wbMR. Eligible men had an elevated level of prostate-specific antigen (PSA) (>0.2 ng/mL) and high-risk features (Gleason score > 7, PSA doubling time < 10 mo, or PSA > 1.0 ng/mL) with negative or equivocal conventional imaging results. PET was interpreted with mpMR and wbMR in consensus by 2 radiologists and compared with prospective interpretation of PET or MRI alone. Performance measures of each modality (PET, MRI, and PET/mpMR-wbMR) were compared for each radiotracer and each individual patient (for 18F-FCH, or 68Ga-PSMA for patients who had 68Ga-PSMA PET) and to a composite reference standard. Results: There were 86 patients with PET (18F-FCH [n = 76] and/or 68Ga-PSMA [n = 26]) who had mpMR and wbMR. Local tumor recurrence was detected in 20 of 76 (26.3%) on 18F-FCH PET/mpMR, versus 11 of 76 (14.5%) on 18F-FCH PET (P = 0.039), and in 11 of 26 (42.3%) on 68Ga-PSMA PET/mpMR, versus 6 of 26 (23.1%) on 68Ga-PSMA PET (P = 0.074). Per patient, PET/mpMR was more often positive for local tumor recurrence than PET (P = 0.039) or mpMR (P = 0.019). There were 20 of 86 patients (23.3%) with regional nodal metastases on both PET/wbMR and PET (P = 1.0) but only 12 of 86 (14%) on wbMR (P = 0.061). Similarly, there were more nonregional metastases detected on PET/wbMR than on PET (P = 0.683) or wbMR (P = 0.074), but these differences did not reach significance. Compared with the composite reference standard for the detection of disease beyond the prostatic fossa, PET/wbMR, PET, and wbMR had sensitivity of 50%, 50%, and 8.3%, respectively, and specificity of 97.1%, 97.1%, and 94.1%, respectively. Conclusion: Interpretation of PET/mpMR resulted in a higher detection rate for local tumor recurrence in the prostatic bed in men with biochemical failure after radical prostatectomy. However, the addition of wbMR to 18F-FCH or 68Ga-PSMA PET did not improve detection of regional or distant metastases.-
dc.subjectbiochemical recurrence-
dc.subjectProstate cancer-
dc.titleThe Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of 18F-Fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy.-
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of nuclear medicine : official publication, Society of Nuclear Medicine-
dc.identifier.affiliationUniversity of Toronto, Toronto, Canada.-
dc.identifier.affiliationUniversité Laval, Quebec, Canadaen
dc.identifier.affiliationSt. Vincent's Hospital, Sydney, Australiaen
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationPeter MacCallum Cancer Centre, Melbourne, Australiaen
dc.identifier.affiliationEastern Health Clinical School, Monash University, Box Hill, Victoria, Australiaen
dc.identifier.affiliationRoyal Marsden Hospital, London, United Kingdom-
dc.identifier.affiliationUniversity College London, London, United Kingdom-
dc.identifier.affiliationUniversity of Toronto, Toronto, Canada-
dc.identifier.affiliationLondon Health Sciences Centre, Ontario, Canada-
dc.identifier.affiliationMcMaster University, Hamilton, Ontario Canada-
dc.identifier.affiliationRoyal Marsden Hospital, London, United Kingdom..-
dc.identifier.affiliationUniversity College London, London, United Kingdom-
dc.type.austinJournal Article-
dc.type.austinMulticenter Study-
dc.type.austinResearch Support, Non-U.S. Gov't-, Andrew M
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.languageiso639-1en- Newton-John Cancer Research Institute- Imaging and Therapy- Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jun 14, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.